JP2015526504A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015526504A5 JP2015526504A5 JP2015529186A JP2015529186A JP2015526504A5 JP 2015526504 A5 JP2015526504 A5 JP 2015526504A5 JP 2015529186 A JP2015529186 A JP 2015529186A JP 2015529186 A JP2015529186 A JP 2015529186A JP 2015526504 A5 JP2015526504 A5 JP 2015526504A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- amount
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 18
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 229940124683 HCV polymerase inhibitor Drugs 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 229940122604 HCV protease inhibitor Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12182551.7 | 2012-08-31 | ||
| EP12182551 | 2012-08-31 | ||
| EP12185890.6 | 2012-09-25 | ||
| EP12185890 | 2012-09-25 | ||
| PCT/IB2013/058138 WO2014033668A2 (en) | 2012-08-31 | 2013-08-30 | Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015526504A JP2015526504A (ja) | 2015-09-10 |
| JP2015526504A5 true JP2015526504A5 (enExample) | 2016-09-23 |
Family
ID=49920362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015529186A Pending JP2015526504A (ja) | 2012-08-31 | 2013-08-30 | Ｈｃｖの大環状プロテアーゼ阻害剤と、非ヌクレオシドｈｃｖ阻害剤と、リトナビルとの組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150209366A1 (enExample) |
| EP (1) | EP2890378A2 (enExample) |
| JP (1) | JP2015526504A (enExample) |
| KR (1) | KR20150046083A (enExample) |
| CN (1) | CN104780921A (enExample) |
| AU (1) | AU2013311025A1 (enExample) |
| BR (1) | BR112015003913A2 (enExample) |
| CA (1) | CA2881052A1 (enExample) |
| IL (1) | IL237049A0 (enExample) |
| MX (1) | MX2015002684A (enExample) |
| RU (1) | RU2015111491A (enExample) |
| WO (1) | WO2014033668A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI454476B (zh) | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物 |
| CN106727516A (zh) * | 2017-01-10 | 2017-05-31 | 山东省立医院 | 一种治疗丙型肝炎的药物组合物 |
| US20210261111A1 (en) | 2018-06-27 | 2021-08-26 | Robert Bosch Gmbh | Method for operating a hybrid powertrain with an electric machine, an internal combustion engine and a variable transmission |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| PE20070211A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| TWI454476B (zh) | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物 |
| SG173772A1 (en) * | 2009-02-27 | 2011-09-29 | Ortho Mcneil Janssen Pharm | Amorphous salt of a macrocyclic inhibitor of hcv |
| US20130028865A1 (en) * | 2010-04-13 | 2013-01-31 | Medivir Ab | Combination of a Macrocyclic Inhibitor of HCV, A Non-Nucleoside and a Nucleoside |
-
2013
- 2013-08-30 MX MX2015002684A patent/MX2015002684A/es unknown
- 2013-08-30 CN CN201380045145.7A patent/CN104780921A/zh active Pending
- 2013-08-30 BR BR112015003913A patent/BR112015003913A2/pt not_active IP Right Cessation
- 2013-08-30 WO PCT/IB2013/058138 patent/WO2014033668A2/en not_active Ceased
- 2013-08-30 AU AU2013311025A patent/AU2013311025A1/en not_active Abandoned
- 2013-08-30 JP JP2015529186A patent/JP2015526504A/ja active Pending
- 2013-08-30 EP EP13818373.6A patent/EP2890378A2/en not_active Withdrawn
- 2013-08-30 CA CA2881052A patent/CA2881052A1/en not_active Abandoned
- 2013-08-30 RU RU2015111491A patent/RU2015111491A/ru not_active Application Discontinuation
- 2013-08-30 US US14/422,005 patent/US20150209366A1/en not_active Abandoned
- 2013-08-30 KR KR1020157005596A patent/KR20150046083A/ko not_active Withdrawn
-
2015
- 2015-02-02 IL IL237049A patent/IL237049A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011528713A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| RU2013119607A (ru) | Полициклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний | |
| JP2016508134A5 (enExample) | ||
| JP2009535352A5 (enExample) | ||
| RU2014122154A (ru) | Композиции, пригодные для лечения вирусных заболеваний | |
| JP2017531038A5 (enExample) | ||
| JP2013507439A5 (enExample) | ||
| ME02321B (me) | Antivirusna jedinjenja | |
| JP2015024998A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2013542247A5 (enExample) | ||
| JP2010077141A5 (enExample) | ||
| JP2015521156A5 (enExample) | ||
| EA201200096A1 (ru) | Фармацевтическая композиция ингибитора протеазы вируса гепатита c | |
| JP2012255026A5 (enExample) | ||
| JP2014504643A5 (enExample) | ||
| SI2932970T1 (en) | Antiviral therapy | |
| JP2019526596A5 (enExample) | ||
| JP2019515908A5 (enExample) | ||
| JP2015522018A5 (enExample) | ||
| JP2015516419A5 (enExample) | ||
| JP2016515550A5 (enExample) | ||
| JP2015526504A5 (enExample) | ||
| JP2014148552A5 (enExample) |